P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026

P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

Treatment with brentuximab vedotin yielded early alleviation of pruritus and progressive resolution of lesions by the third cycle, with favorable tolerability. This case serves as a foundation for a narrative review that underscores the diagnostic challenges associated with "allergic-appearing" eruptions in patients with T-cell lymphoma, the importance of integrated staging utilizing TNMB (skin/blood) in conjunction with Lugano/Deauville positron emission tomography-computed tomography to assess systemic burden and therapeutic response, and biologically informed systemic therapy options aligned with comorbidities, including emerging targeted treatment strategies.

P2/3, N=370, Not yet recruiting, Polska Grupa Badawcza Chloniakow

For multifocal or relapsed disease, brentuximab vedotin demonstrates the most robust prospective data and has reshaped the treatment landscape; however, alternative systemic therapies, including methotrexate and retinoids, remain relevant in selected patients. Overall, current management is supported largely by non-randomized data, and key gaps remain in risk stratification, optimal sequencing of therapies, and management of uncommon aggressive variants.

P=N/A, N=70, Recruiting, Takeda | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Jan 2027

P2, N=49, Completed, Northwestern University | Unknown status --> Completed

P2, N=20, Recruiting, New York Medical College | Active, not recruiting --> Recruiting

An analysis of early phase clinical trial data reveals encouraging efficacy, with high rates of durable complete responses observed even in heavily pretreated patients who have failed brentuximab vedotin therapy...While these findings are promising, it is essential to acknowledge that the current evidence base remains preliminary, derived from small, heterogeneous patient cohorts and requiring validation in larger, more definitive trials with extended follow-up. By successfully addressing the challenge of fratricide, anti-CD30 CAR-T therapy holds the potential to become a transformative and potentially curative option for patients with R/R ALCL and may offer a valuable blueprint for developing effective immunotherapies against other T-cell malignancies.

P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P1, N=58, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns